About 19 results found for searched term "AB21" (0.084 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1803 | Laquinimod | Immunology/Inflammation |
| ABR-215062 | ||
| Laquinimod (ABR-215062) is a new orally active immunoregulator effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. | ||
| M2028 | Fludarabine (NSC 118218) | STAT |
| Fludara; NSC 118218; Fludarabinum | ||
| Fludarabine is a STAT1 activation inhibitor and a DNA synthesis inhibitor. | ||
| M9307 | TC-S 7005 | PLK |
| ABM-9921 | ||
| TC-S 7005 is a potent and selective polo-like kinase 2 (PLK2) inhibitor (IC50 = 4 nM). | ||
| M9633 | Tasquinimod | HDAC |
| ABR-215050 | ||
| Tasquinimod is an oral antiangiogenic and S100A9 inhibitor. | ||
| M9710 | Roquinimex | TNF Receptor |
| LS2616; FCF89; Linomide; ABR212616 | ||
| Roquinimex (LS2616; FCF89) is a quinoline-3-carboxamide with potential antineoplastic activity, which increases NK cell activity and macrophage cytotoxicity. | ||
| M10347 | Abemaciclib (LY2835219) | CDK |
| LY2835219 free base | ||
| Abemaciclib (LY2835219) is a best-in-class, selective and effective dual inhibitor of CDK4 and CDK6, which inhibits CDK4/CDK6 activity with IC50 of 2 nM and 10 nM respectively. | ||
| M24605 | Concizumab | Others |
| NN 7415; mAb 2021 Anti-TFPI Recombinant Antibody | ||
| Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia. | ||
| M24632 | Anatumomab mafenatox | Others |
| ABR-214936 | ||
| Anatumomab mafenatox (ABR-214936) is a 73 KDa recombinant protein to recognize the tumor-associated antigen 5T4, which is widely expressing in malignancy. Anatumomab mafenatox is between a modified form of SEA and a murine Fab. The main side effects of Anatumomab mafenatox are reported to include fever, low blood pressure, pain, nausea and drowsiness. | ||
| M24674 | ABP 215 | VEGFR/PDGFR |
| ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research. | ||
| M24821 | Eftozanermin alfa | Apoptosis |
| ABBV-621 | ||
| Eftozanermin alfa (ABBV-621) is a second-generation tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors 4/5. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies. | ||
| M24944 | Serclutamab talirine | Drug-Linker Conjugates for ADC |
| ABBV-321 | ||
| Serclutamab talirine (ABBV-321) is an EGFR-targeted antibody-drug conjugate (ADC). Serclutamab talirine is consisted of an antibody (AM-1-ABT-806) directed against activated EGFR and a pyrrolobenzodiazepine (PBD) dimer. Serclutamab talirine shows potent antitumor activity. | ||
| M25246 | Naptumomab estafenatox | Others |
| ABR-217620; ANYARA | ||
| Naptumomab estafenatox (ABR-217620) is a tumor targeting superantigen (TTS). Naptumomab estafenatox is a fusion protein containing an anti-5T4 antibody and a SEA/E-120 superantige. Naptumomab estafenatox can be used for the research of lung cancer. | ||
| M40737 | AB-521 | HIF |
| AB-521 is a HIF-2α inhibitor that can be used in studies related to hepatocellular carcinoma and renal cell carcinoma. | ||
| M42702 | AB21 oxalate | Sigma Receptor |
| AB21 oxalate is a potent and selective S1R antagonist with Kis of 13, 102 nM for S1R and S2R. | ||
| M42703 | AB21 | Sigma Receptor |
| AB21 is a potent and selective S1R antagonist with Kis of 13, 102 nM for S1R and S2R. | ||
| M43482 | Pimicotinib | CSF-1R (c-Fms) |
| ABSK021 | ||
| Pimicotinib is a novel, orally bioavailable, highly selective small-molecule inhibitor of colony-stimulating factor 1 (CSF-1) with antitumor activity and less inhibitory effects on c-Kit and PDGFR. | ||
| M45217 | ABSK121 | FGFR |
| ABSK121 is an orally active, highly selective small molecule FGFR inhibitor. | ||
| M49938 | Glecirasib | Ras |
| JAB-21822; KRAS G12C inhibitor 36 | ||
| Glecirasib is a potent, irreversible, orally active KRAS G12C inhibitor for studies related to KRAS G12C-mediated cancers. | ||
| M50226 | ABI-H2158 | Others |
| ABI-H2158 is an HBV capsid inhibitor that indirectly inhibits cccDNA. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
